Study points to serious risks from Evista

A new study of Eli Lilly's blockbuster osteoporosis drug Evista demonstrated significantly higher risk of strokes and blood clots compared to women taking a placebo. Authors of the study say that patients need to compare their risk of strokes and blood clots against the protection Evista provides against osteoporosis and breast cancer. The study's authors said that patients taking Evista had a 49 percent increase in the risk of death from stroke and a 44 percent increase in the risk of blood clots. Evista is a big earner for Lilly, bringing in $1 billion last year.

- take a look at the report [1] on Evista from The Indianapolis Star